2020, Number 3
Presentatlon of a clinical case of cerebral cystlcercosis treated medically with a new drug
Robles C, Chavarría CM
Full text
Language: English/Spanish
References: 19
Page: 1-16
PDF size: 766.06 Kb.
ABSTRACT
Cysticercosis 15 a great danger in latinoamerican countries and some others, no medical treatment is known surgery is satisfied in small percentage of cases; the experiments made in swine treatment demonstrated that it is possible to exterminate the parasites lodged in muscular tissue as in the nervous centers; this was the initial phase of the investigations performed by one of the authors (Chavarría). Once this objective was achieved, it was planned with Dr. Robles to transfer results on man, and treatment was applied to a six years old boy. At first requirements were accomplished for experimenting on humans which Helsinki Chart Indicates, one act was sta blished with the patient’s parents, who were well aware that of veterinary medication or treatment would be used whose action and reactions are unknown on humans. This case was studied and used with advantage, diagnosis was made and verified by various institutions, it was parenchymatous, multiple, intracerebral cysticercosis with supra and infratentorial lesions, with fatal prognosis, which fully proven by clinical observations. The patient was hospitalized in a trust worthy medical center and with complete laboratory resources, good medical staff, equipment etc. in order to meet any emergency. Medication was given at a dose of 50 mg/patient’s weight every six hours during two weeks. In order to prevent complications the senior author considered the use of Prednisone convenient at adose of 50 mg per day orally during the duration of the research period. Fenobarbital was also administered at the dose 0.05 g daily with very good promising results. The patient was examined clinically every day, vital signs taken every six hours, frequent determinations hematic biometry, urine, blood chemistry, protrombine dosifications, determinations on blood coagulation and bleeding time, liver functioning, dosification on bilirubins, transaminases and lactic dehydrogenase. No reaction of intolerance of allergic reaction has been observed. With fatal prognosis of this clinical form of cysticercosis, which various physicians made known to the patient’s family and on which we agreed upon the case was ideal in our opinion to be used for the first time on a human being, one medication already tested on voluntary people with results of inocuity and complete tolerance. The patient had been treated daily with 16 mg of Dexametasona and 7 mg of Fenobarbltal. He presented two months before violent picture of cranial hypertensioncephalea, vomit, oculogyration to right, convulsive crisis, diplopia and papillary oedema. CFT (Nieto) positive to 1.0 ml. Diagnosis of billateral, generalized, diffused, and intracerebral cysticercosis and moreover taenlasis. Electroencephalogram: disorganization and identification of diffuse base in both cerebral hemispheres. CAT: multiple granulomatose processes supra and infratentorials with peripheral cedema.After this treatment the patient is completely asymptomatic and has received no further medical treatment during the past three months. The laboratory tests on the above mentioned control are normal. CRL Pandy, bacterioscopy and cultures negatives. CFT negative. Normal electroencephalogram. Immunological reactions suggest that the parasites are exterminated, the antigenic reactions have disappeared. X rays: disappear completely the annular shadows.
Conclusions may be trusted that the praziquantel is efficient for the treatment of cerebral cysticercosis, it exterminates the cysticerci and cures the disease. in the present case, there were neither allergyc reaction or intolerance or toxic phenomena.
REFERENCES